Invasive diagnostic prenatal testing can provide the most comprehensive information about the genetic status of a fetus. Noninvasive prenatal screening methods, especially when using cell-free DNA ...

Cell-free DNA (cfDNA) refers to fragments of DNA circulating in the bloodstream that originate from various sources, including dead or dying cells. In recent years, cfDNA has emerged as a promising ...

As cost of sequencing continues to drop, the throughput and complexity of NGS assays have risen precipitously. At the same time, the types of samples being used for these assays have expanded as ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample can effectively diagnose and stage bladder cancer, offering a much-needed ...

Next-generation sequencing (NGS) is an important component of first-line treatment selection for metastatic non–small-cell lung cancer (NSCLC) and is typically ordered by medical oncologists in the ...

A new research paper was published in Oncotarget's Volume 16 on January 21, 2025, titled "Assessment of cfDNA release dynamics during colorectal cancer surgery." Researchers from the University of ...

Cell-free DNA (cfDNA) can act as a powerful biomarker for cancer research, from disease onset to therapy selection and minimal residual disease (MRD) measurement. Next-generation sequencing (NGS) has ...

Correlation between comprehensive genomic profiling (CGP) utilizing tissue-based testing (T-CGP) and cell-free DNA (cfDNA) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC). This is an ...

Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "Cell Free DNA (cfDNA) Testing Market Outlook to 2028 & 2033" report has been added to ResearchAndMarkets.com's offering. The cell free DNA (cfDNA) ...

Bold Capital and Bold Longevity Growth join strategic partners and previous investors as the platform moves towards commercialization for products in rheumatoid arthritis and cancer Aqtual is actively ...

Horizon Discovery (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announces the launch of its new cell line-derived epidermal growth ...